Arkolith/Insider Trading/ACAD/Form 4

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICERACADIA PHARMACEUTICALS INC (ACAD) · full profile →Form 4 · filed Nov 19, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$243K
Net Open-Market Flow
-$243K
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 18, 2025Sell(S)10K$23.69$243K53K
Nov 17, 2025Option exercise(M)10K——54K
Nov 17, 2025Option exercise(M)10K——64K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 17, 2025Option exercise(M)10K—$00
Nov 17, 2025Option exercise(M)10K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001899977-25-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML